Published Date:2021-06-08 Original Link:https://www.onenessbio.com/en/news_detail46_3.htm No 1 Date of announcement 2021/06/08 Time of announcement 21:27:47 Subject An IND was submitted to US FDA for a phase II clinical trial of FB704A, an anti-IL6 mAb developed by Oneness, for treating severe COVID-19.      To which item it meets paragraph 10 Date of events 2021/06/08 Statement 1.Product:FB704A...Read More